Skip to main content
Clinical Trials/JPRN-UMIN000023873
JPRN-UMIN000023873
Completed
未知

A study of evaluation to the predictive biomarker of Nivolumab in peripheral blood and pleural effusion. - A biomarker study of of Nivolumab in blood and pleural effusion.

Respiratory Medicine, Allergy and Rheu matic Diseases Osaka University Graduate School of Medicine0 sites10 target enrollmentAugust 31, 2016

Overview

Phase
未知
Intervention
Not specified
Conditions
previously treated patients with advanced non-small-cell lung cancer
Sponsor
Respiratory Medicine, Allergy and Rheu matic Diseases Osaka University Graduate School of Medicine
Enrollment
10
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 31, 2016
End Date
December 31, 2021
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Respiratory Medicine, Allergy and Rheu matic Diseases Osaka University Graduate School of Medicine

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)With interstitial pneumonia or pulmonary fibrosis on a chest X\-ray 2\)Clinically significant drug allergy 3\)Presencee of other active malignancy 4\)With pericardial effusion, pleural effusion and ascites in need of treatment of drainage 5\)Positive serum HBs antigen 6\)With severe infection, cardiac diseases, diabates, hypertention, other severe complication 7\)Patients received palliative radiotherapy for brain metastases and bone metastases, except for the primary lesion within 2weeks. 8\)Pregnancy or lactating patients

Outcomes

Primary Outcomes

Not specified

Similar Trials

Unknown
Not Applicable
Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in ramucirumab plus paclitaxel therapy for elderly patients with unresectable or recurrent gastric cancerunresectable or recurrent gastric cancer
JPRN-UMIN000021743Tohoku Clinical Oncology Research and Education Society (T-CORE)30
Completed
Not Applicable
Analysis of predictive biomarker and analysis of correlations between toxicities and SNPs that can be related to pharmacokinetics, in trifluridine/tipiracil hydrochloride therapy for previously fluoropyrimidine-treated elderly patients with unresectable or recurrent colorectal cancerColorectal cancer
JPRN-UMIN000021742Tohoku Clinical Oncology Research and Education Society (T-CORE)20
Recruiting
Not Applicable
Prospective validation of the prognostic biomarker CD8+ TEMRA cells for disturbed fracture healing.S82.1S82.2S82.3S82.7S82.11S82.18S82.31S72S72.1S72.2S72.3S72.4S72.7S72.8Fracture of upper end of tibiaFracture of shaft of tibiaFracture of lower end of tibiaMultiple fractures of lower legFracture of femurPertrochanteric fractureSubtrochanteric fractureFracture of shaft of femurFracture of lower end of femurMultiple fractures of femurFractures of other parts of femur
DRKS00010872Charité Universitätsmedizin Berlin / Berlin-Brandenburger Centrum für Regenerative Therapien / Julius Wolff Institut800
Recruiting
Not Applicable
A biomarker assessment study to investigate the influence of high-frequency chest wall oscillations on the clearance of cerebrospinal fluid biomarkers
NL-OMON51372Centre for Human Drug Research34
Not yet recruiting
Not Applicable
A prospective observational study of biomarkers for Second-line FOLFIRI plus Aflibercept treatment in patients with metastatic colorectal cancer comparing to FOLFIRI plus beVacizumab: an Exploratory biomarker study.colorectal cancer
JPRN-UMIN000038508Kyoto University Hospital70